Roche's MagNA Pure LC 2.0 System for Monitoring DNA in Therapeutic Proteins and Monoclonal Antibody Drugs
To ensure product safety, clearance of host-cell DNA is essential when manufacturing therapeutic proteins and monoclonal…
To ensure product safety, clearance of host-cell DNA is essential when manufacturing therapeutic proteins and monoclonal…
A research team led by Dr. Michel Bouvier at the Institute for Research in Immunology and Cancer (IRIC) of the Universit…
A team of researchers from Roche (SIX: RO, ROG; OTCQX: RHHBY), including scientists from Roche Pharma Research and Early…
Cardiac toxicity is a major concern in drug development and it is imperative that clinical candidates are thoroughly tes…
Cardiotoxicity, which results when drugs adversely affect the heart, explains why roughly one third of new pharmaceutica…
Label-free technologies have entered the stage of cellular drug discovery and high-throughput screening (HTS). For the m…
The new xCELLigence RTCA HT Instrument from Roche (SIX: RO, ROG; OTCQX: RHHBY) rounds out the Diagnostics Applied Scienc…
Cellular Dynamics International (CDI) announced today their partnership with ACEA Biosciences to bring early and accurat…
Researchers at the University of Maryland Marlene and Stewart Greenebaum Cancer Center have studied the involvement of "…
Gcoupled protein receptors (GPCRs), also known as 7transmembrane proteins, constitute the single largest class of therap…